Pharmabiz
 

Akorn sells its subsidiary ECR to Valeant Pharmaceuticals for $41mn

Lake Forest, IllinoisMonday, June 23, 2014, 15:00 Hrs  [IST]

Akorn, has sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its fiscal second quarter earnings call in early August.

Raj Rai, Akorn’s chief executive officer, commented, “While ECR is a solid platform of branded products, it is not a strategic fit to our business model of focusing on niche dosage forms. We believe this asset has better prospects for future growth and development under the leadership of a company like Valeant.”

Akorn, Inc. is a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York and Paont resophthalmic, injectable and niche, non-sterile pharmaceuticals.

 
[Close]